On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Oral Ulcers in Behçet's Disease
BID, twice daily; RELIEF, Researching Oral Apremilast Safety and Efficacy in Behçet's Disease.
Baseline demographics and disease characteristics were balanced between study arms, with a mean duration of BD diagnosis 6.8 years; mean oral ulcer count of 4.2 (Otezla) and 3.9 (placebo).1,3
Measures of oral ulcers:
Selected inclusion criteria:
Selected exclusion criteria:
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of Apremilast for oral ulcers in Behçet’s Syndrome. N Engl J Med. 2019; 381:1918-1928.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations